Tesofensine is a serotonin–noradrenaline–dopamine reuptake inhibitor (SNDRI) used off-label primarily for weight loss, appetite suppression, and cognitive support. Users typically run daily oral doses ranging from 250 µg to 1 mg, with 500 µg serving as the common community modal dose. While users occasionally report changes in sleep patterns and dream intensity, the primary tradeoff is that the evidence base remains thin, as the substance lacks FDA approval and most exploratory indications lack published results. Injection-site reactions, nausea, and fluid retention have not been consistent themes in user reports.
Data last updated
Evidence shape
Tesofensine possesses moderate clinical evidence, primarily centered on obesity treatment. While 11 trials are registered, only four have posted results, and the majority of the ten mapped indications remain exploratory or limited to single-trial investigations. The research quality is constrained by this narrow scope, as most potential applications lack follow-up data or broader validation beyond initial, small-scale studies. This reliance on a few blinded trials with a combined total of 159 participants highlights a significant gap between the peptide's theoretical breadth and the actual volume of published human data.
Efficacy signal
Completed and classified human trials only. Recruiting studies and trials without clean primary-endpoint classification are excluded from these percentages.
+5.0 Participants · 1 classified trial · 1 RCT · n=21
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Anecdotal side effects
price offers can be sorted by column · 5 out-of-stock offers not shown
How Tesofensine is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In research trials, Tesofensine was taken orally at 500 mcg daily, with doses ranging from 500 mcg to 1 mg per day. No specific cycling protocol was reported.
In clinician practice, Tesofensine is taken orally each day, most often at 250 mcg, though reported doses range from 250 mcg up to 1 mg daily.
Most users did not specify a dosing schedule; among the minority who did, daily administration was typical, often around 500 mcg (with reported doses ranging from 125 mcg to 25 mg).